Predictive Oncology Inc (POAI)

[Cphelan23]

IM NOT LEAVINGGGGG HODLLLL

[Cphelan23]

Get ready y’all. It’s time.

[Goat_1]

Two Top Researchers find Breakthrough Discoveries using Predictive Oncology’s Wholly Owned Subsidiary, TumorGenesis’s Tec...
February 17 2021 - 08:30AM
GlobeNewswire Inc.

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced today that the products of its wholly owned subsidiary, TumorGenesis, aided researchers in the understanding of how ovarian cancer cells migrate outside the abdominal cavity. The research, completed by a top-tier laboratory in Massachusetts, used TumorGenesis’s media to capture, culture, and identify how these cells ‘break through’ the protective lining in the abdomen, called the omentum or abdominal membrane.
This discovery means that drugs could be targeted against that receptor site of the omentum or lining to effectively ‘block’ the metastasis of re-occurring ovarian cancer. Nearly 64% of women die from ovarian cancer in the US. The current patient population has over 21,400 new cases with nearly 13,700 dying per year, mostly from re-occurring tumors.

The second big breakthrough was done by another topflight researcher in the UK that used the media to isolate, identify and study a mechanism for treatment for some ovarian cancer patients. The treatment, a PARP inhibitor, inhibits the enzyme that in cancer cells repairs damaged DNA. This treatment sometimes accelerates the metastasis, often killing the patient.

By successfully growing the cell lines used for the treatment, the researchers found a defective enzyme that can be easily blocked by a class of compounds called PARGs (poly (ADP-ribose) glycohydrolase). If the enzymes are blocked, the patients treated are expected to then have a positive response to continued PARP-PARG treatment.

“Both targets of the research aided by TumorGenesis’s technology, blocking the omentum penetration and blocking the enzyme that accelerates a response to PARP treatment, once developed and approved, represent several billion dollars in future revenues for biotech or pharma companies. Three currently available PARP inhibitors, each becoming resistant to ovarian cancer over time, generate $2.8 billion in revenue for such companies. That is why TumorGenesis is expanding its product lines, offering services, and helping pharma, biotech, and researchers around the world to unravel cancer’s mysteries,” said CEO Dr. Carl Schwartz.

About Predictive Oncology Inc.

Predictive Oncology (NASDAQ: POAI) operates through three segments (Skyline, Helomics and Soluble Biotech), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech.

Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement, and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins, and protein complexes.

Forward-Looking Statements

Certain matters discussed in this release contain forward-looking statements. These forward-looking statements reflect our current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about our operations and the investments we make. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, plans and objectives of management are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “would,” “target” and similar expressions are intended to identify forward- looking statements, although not all forward-looking statements contain these identifying words. Our actual future performance may materially differ from that contemplated by the forward-looking statements because of a variety of factors including, among other things, factors discussed under the heading “Risk Factors” in our filings with the SEC. Except as expressly required by law, the Company disclaims any intent or obligation to update these forward-looking statements.

Investor Relations Contact:

Landon Capital
Keith Pinder
[phone]
[e-mail]

[2020trader]

target now $3

[VisionaryInc]

Over 5 million sold to Oasis for equity line.

Only way they'd profit is to short them.

Can't see the recent increases staying long on no solid news and no positive change in books

Lotta micros seeing increases from all the extra stimulus money going around.

[wesley_]

$1.95 nice

[Cphelan23]

Sounds like big pharma rejected us

[Paullee]

Predictive Oncology’s Wholly Owned Subsidiary Helomics announces the start of its drug repurposing project using its ground-breaking PeDAL™ platform for ovarian cancer


More content below
Predictive Oncology Inc.
Mon, February 8, 2021, 8:30 AM


More content below

POAI
-5.00%
MINNEAPOLIS, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced today that it will start an in-house drug repurposing project, focused on ovarian cancer, using its proprietary AI-driven, patient centric discovery platform – PeDAL™. The project will use PeDAL to rapidly and cost-effectively profile panel of existing drugs against hundreds of patient cell lines. This process will generate data on which compounds are active against which specific patient profile(s), delivering both proof data for the PeDAL approach and valuable Intellectual Property (IP) for the company.

“With our Helomics division’s deep experience in clinical profiling of patient tumor drug response, plus our unique PeDAL platform, we have all the components to perform in-house drug repositioning and even full drug discovery. We are very excited to kick-off this first project focused on ovarian cancer. Our expectations are that the project will have significant value by generating proof data for our PeDAL approach, which will be useful in our commercial discussions with Pharmaceutical companies. In addition, the project will also demonstrate the long-term value of Helomics unique data,” explained Dr. Carl Schwartz, CEO of Predictive Oncology.

“Looking forward, we strongly believe successful execution of this project will demonstrate that Predictive Oncology is emerging as a leader in AI-driven drug discovery,” commented Dr. Schwartz.

[Cphelan23]

We have positioned Helomics to compete in the marketplace,” he said. “The original basis of Helomics… was that physicians or hospitals would send their tumors to this company and they would test the tumors with the known therapies of the day… In that process, [Helomics] accumulated over 150,000 tumors covering over 137 different cancers… That database is the largest of its kind in the world… With that data, and the fact that we’ve sequenced these tumors, we have shown that we can provide quality information to anyone who needs it. There’s a lot going on at Helomics. We think we’ve validated the company. We’ve got assets that are one-of-a-kind in the world, and we think we are on our way to where we wanted to be when we first purchased this company a couple of years ago.”

Please listen to the full interview with Predictive Oncology CEO Carl Schwartz at https://nnw.fm/e0fDA.

[77Port]

The Company has regained compliance with the minimum bid price requirement set forth in Rule 5550(a)(2) of the Nasdaq Listing Rules (the “Minimum Bid Price Requirement”).
The Company had previously received written notice from Nasdaq in October 2020 indicating that because the closing bid price per share had been below $1.00 for a period of 30 consecutive business days and that the Company did not meet the Minimum Price Bid Requirement. According to the recent notification letter, the staff of Nasdaq has determined that for the last 10 consecutive business days, from January 19, 2021 to February 1, 2021, the closing bid price of the Company’s common stock has been at $1.00 per share or greater, and the Company has regained compliance with the Minimum Bid Price Requirement, and the matter is now closed.

[77Port]

equity research firm, Litchfield Hills Research LLC, released its first analyst coverage report on (Nasdaq: POAI), rating the Company a "Buy" under its three-tiered (buy-hold-sell) rating system.
Litchfield Hills Research adheres to FINRA standards for quality and objectivity. The Litchfield Hills Research Department certifies its report is compliant with FINRA research rules 2241, 3110, the Litchfield is registered with FINRA, and the report has been reviewed by a Supervisory Senior Analyst. Litchfield’s price target, financial models, peer comparisons, and investment thesis are developed without input from management of the company, and they performed their own due diligence.

The research report is MiFID II compliant and is classified as minor non-monetary benefit under MiFID II. It is accessible on Bloomberg, FactSet, NASDAQ, NYSE Connect, S&P Cap IQ, Thomson Reuters (Refinitiv) and 12 other platforms around the globe. It will be posted to the research firm’s website http://www.hillsresearch.com/current-research/.

About Predictive Oncology Inc.

Predictive Oncology (NASDAQ: POAI) operates through three segments (Skyline, Helomics and Soluble Biotech), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech.

Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement, and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins, and protein complexes.

[Cphelan23]

Would not invest here management a bunch of scam artists sad

[Cphelan23]

Imagine being Bob Myers the CFO - he has worked for this company for much of his depressing adult life. Such a sad life to lead I don’t know how he does it. Clearly he just eats all day to cope. Sad.

[77Port]

POAI. Say this outloud and it kind of sounds like a fart. Just goes to show, though, that some farts don't smell bad. Today the news was very very good.

Who would have ever thought somebody would buy Ovarian cancer? More importantly, who would have thought a company would figure out how to package and sell it to advance the possibility of curing it?

https://ih.advfn.com/stock-market/NASDAQ/predictive-oncology-POAI/stock-news/84093868/predictive-oncology-reports-that-its-wholly-owned

[77Port]

I hear you. I've ridden this broken company down into the gutter, too. Mismanagement or bad timing? it's unclear to me, or maybe both. These guys are definitely experts in sleight of hand tricks to stay alive. But that's the world of small investing; survival of the fittest. We're all underwater here.

There are two questions: are the stories all lies or are the products real?

From what I can tell, the products are real even if the sleight of hand, continual filings moving things around drives me crazy.

What's the option? Sell for a loss? Or hold and see if these products can find their right niche? Seems to me medical waste, AI, DNA and cancer research with a warehouse of cancer samples is a bet worth staying with.

These docs are not nice to us investors. I imagine they're mad, too. They wanted to hit it big a decade ago and then the world kept falling apart. One of these days we all hope they find the right hit which catapults them into the big leagues. If that happens, this board quickly changes.

[stupidRICHxASAP]

GLTA

[Bona Vista]

Yes only a matter of time before POAI moves to the Pink Sheets, NO one in their right mind would ever consider BUYING shares in this company.

Knowing its management and years of history with all their different corporate name changes, one can understand why this company can't even get a quorum to vote on an amendment presented to their shareholders.

I can assure you and everyone else holding shares in POAI that you are losing money, don't expect anything good coming out this year and only another R/S will ever get the price above $2.00.

[stupidRICHxASAP]

Great action today $$$ only a matter of time

[Bona Vista]

No you are totally wrong on the credit you give to POAI and its management, as I have always posted for years is that POAI is only good for 2 things and that is, keeping their share price below $1.00 on a constant basis and their continuation of R/S and dilution of their shares.

As of today another 3 million hitting the market, NOTHING this company has done or will do can benefit the shareholders, best thing one should do is SELL whatever they have and move on.

[stupidRICHxASAP]

BREAKING

Predictive Oncology Announces $3,074,007 Registered Direct Offering Priced At-The-Market under Nasdaq Rules

3,650,840 shares of its common stock, at a purchase price of $0.842 per share

https://www.globenewswire.com/news-release/2021/01/08/2155595/0/en/Predictive-Oncology-Announces-3-074-007-Registered-Direct-Offering-Priced-At-The-Market-under-Nasdaq-Rules.html

[77Port]

Hate them for their arrogance and lack of transparency. But they're a dog trying to catch the fox and they're on the scent. Or maybe they're trying to catch the shuttle to the moon because they are touching one of the sweet spots of the future. Today's report:
Predictive Oncology’s Wholly Owned Subsidiary Helomics completes integration of Quantitative Medicine

Source: GlobeNewswire Inc.

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced today that its wholly owned subsidiary Helomics has completed the integration of Quantitative Medicine’s (QM) novel active-learning Computational Research Engine (CoRE™) with Helomics’ proprietary TumorSpace™ knowledgebase of 150,000 tumor drug response profiles and the TruTumor™ patient primary tumor cell line assay. This integration allows Helomics to offer a revolutionary new AI-driven patient-centric drug discovery service to Pharmaceutical companies that will significantly improve the chances of successfully translating new drugs into the clinic.
“With the completion of the CoRE integration, we are now able to offer our new PeDAL™ (Patient-cEntric Discovery by Active Learning) service to Pharmaceutical companies to allow patient-centric de-risking of compounds early in discovery, resulting in better prioritization of compounds and better coverage of patient diversity. This will dramatically improve the chances of successfully translating discoveries into the clinic, resulting in lowered costs, shortened timelines, and most importantly enhanced "speed-to-patient" for new therapies,” explained Dr. Carl Schwartz, Predictive Oncology, CEO. “We expect to see revenue generating projects that use PeDAL and CoRE in the first half of 2021,” commented Dr. Schwartz

[Cphelan23]

Imagine being Bob Myers and having to tell people what you do for a living.

[slow_feet]

I step out for some lunch, and my POAI jumps +20%.
News? I don't see anything.

[Cphelan23]

Huge sales on the board. Might open .50 Monday. With dilution ongoing

[Cphelan23]

Anyone seen the CFO Bob Myers ? He’s a fat fuck. I can hear him arguing with his wife about who gets the last donut from here

[wesley_]

.77 nice volume

[Giovanni]

anything good

[77Port]

Thanks. It's nice somebody is out there paying attention. We need the robinhood investors to find poai.

[Cphelan23]

Wow epic post. Love it.

[77Port]

No doubt there is more to the story and I'd like to know what it is.

Regarding the vote, clearly what they've done in the past has not worked. So why continue what has not worked? Vote for change.

My take on POAI is this. They have a story of interest (precision med) in a field of interest (sad healthcare in a world of possibility). They are trying to pull a rabbit out of a hat and they are up against the world's most powerful healthcare companies who clearly don't want new competition.

Carl and Bob have a million tricks up their sleeve which drives us crazy. Perhaps it's all a game of 3-Card-Monty. Clearly, neither shareholders nor competitors like them, which is a little bit interesting.

Why aren't they liked? Perhaps it's because they aren't selling the company to a bidder. On the other hand, if they had products of true value, seems like the larger players would have already made attractive offers.

But I see no evidence the POAI products are fraudulent. So, I can't explain this lack of interest.

The STREAMWAY System is interesting and is clearly something of value in a hospital system terrified of its own waste products. In some universe, this is a spin-off with potential.

Helomics and Tumor genesis are both also interesting. I believe the science is real and, therefore, a potential breakthrough.

A year or so ago, I heard a news show about precision medicine and, lo and behold, POAI was named as a "small player." Even the announcer seemed surprised there was a name on the board he had never heard of before. It was an odd moment. Why aren't they mentioned more often? Who did they piss off to be treated so poorly?

And so the big elephant question is: why so little attention? Is POAI a pump and dump or a tiny stock with a big potential?

This is why breakthrough healthcare is such an exciting field to invest in. Tiny stocks can sometimes set the world on fire. The likelihood of POAI being one of these stocks is slim, which is why the stock is back under $1. But at the same time, a small breakthrough would likewise create a 10-100 jump in price. That's the risk. Complain if you must but that's why we're here.

GLTA

[Cphelan23]

Ya ok Carl you sketchy dentist.

Delaware is a haven for public companies. You’ve been there for years.

Much more to the story

DO NOT INVEST HERE

[77Port]

If you're going to vote, the only answer is to vote to lower costs. It's the smart answer. Voting no is cutting off your head because you don't like a haircut.

[Cphelan23]

Such a sketchy company. DO NOT TOUCH

Sketchy management

[Cphelan23]

Vote no on all options. Fuck you Bob Myers and fuck you Dentist Carl! Sketchy mother fuckers.

[Paullee]

nothing happened, did not have a quorum, delayed to 12/31

[77Port]

Did anybody listen to today's shareholder meeting where they voted to save money, leave Delaware for the cheaper fees of Nevada? I went to listen but the meeting ended before I arrived. If you know, please post how the vote went. Either way, we should find out something tomorrow.

[Cphelan23]

Bob Myers CFO of this company refuses to buy shares and keeps making excuses.

DO NOT TOUCH THIS STOCK it is toxic

[77Port]

We will discover the future after next month's meeting when the big stockholder vote is revealed. Leaving Delaware will save the company tons of paper money. Moving to Nevada will allow them more time to grow the Helomics division, the area with the most potential. Until making money is constant, saving money becomes essential. Moving allows POAI more time to make deals with companies who could benefit from their tumor research. Also, perhaps the company will be bought as a snack for one of the larger research companies. If either positive scenario works those of us holding shares may get our money back. If neither work shares may go to zero. Just my take. Thoughts?

[speedstar]

Can someone say anything good, when is this gonna go up ??

[Paullee]

new interview

https://www.networknewswire.com/networknewsaudio/networknewsaudio-predictive-oncology-inc-nasdaq-poai-interview/

[Paullee]

Predictive Oncology CEO Letter to Shareholders
GlobeNewswire
Predictive Oncology Inc.
,GlobeNewswire•October 6, 2020
EAGAN, Minn., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ:POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is pleased to release the CEO’s letter to the shareholders.

To our valued shareholders,

I know you have watched our stock price decline steadily over the past few weeks. I am writing to assure you that there is a lot of encouraging progress to report – in other words, our company is not in the condition that the stock price might indicate. I want to take this opportunity to review where Predictive Oncology stands as of today.

Our cash burn is stable and trending downward. Our revenues are stable and trending upward. Our available cash is adequate for operations and we have the ability to utilize our equity line of credit, which has a remaining amount of over $10 million.

The best news is in the operational progress in our various divisions. Starting with Skyline Medical, this division is self-supporting from a cash standpoint. Sales of disposables used on previously sold machines more than cover the operating expenses of this division, and we continue to sell new machines on a regular basis, adding to future disposables revenues.

Our Helomics division is coming along handsomely. We have launched a restructured clinical test offering to clinicians for ovarian cancer. The response from oncologists to this re-configured test has been excellent and we expect this effort, as well as our other tests, to be revenue generating by year end and should be able to cover the bulk of Helomics operating expenses going forward. We have made solid progress on the UPMC-Magee Women’s Hospital project and are close to completing our AI-driven models of drug response and patient outcomes. We are also finishing the sequencing of the tumors from the patients involved and have completed the “reach back” for patient outcome data (i.e. including data on what happened to the patient). The Magee Study validates our ability to sequence our tumor inventory as well as to do the reach back for patient outcomes. The acquisition and integration of the newly acquired Quantitative Medicine AI software into Helomics’ existing computer model is a major accomplishment. We have begun discussions with large Pharma companies in an effort to form major, multi-year, multi-target, milestone based strategic partnerships. We hope to make more announcements soon.

Our TumorGenesis division has not been resting on its’ laurels. We will be introducing our Ovarian Cell Line Media at the BIO-Europe Conference. This media will allow researchers to isolate and successfully culture ovarian cancer cells that have previously not been cultured. Under the NCI Prevent Cancer Program, TumorGenesis, Cornell Medical and Helomics will coordinate with and seek funding for this program to help identify the best culture media for the studying of mutations that increase the risk of ovarian and breast cancers as well as other types of cancers. TumorGenesis is registering with the U.S. government as a contractor for developmental work in cancer cell capture and screening of compounds for the prevention and treatment of cancer. TumorGenesis Discovery Kits will also launch at the BIO-Europe conference. These kits will allow researchers to study and tag target cancer cells as well as normal cells often associated with tumors and let pathologists screen approved drug therapies across isolated and properly identified ovarian cancer samples from patients.

Last, but certainly not least, is Soluble Biotech. We have moved this division into a new Research Park located in Birmingham, Alabama. This new facility effectively quadruples our Soluble’s office and research space. This state of the art company provides optimized FDA-approved formulations for vaccines, antibodies and other protein therapeutics in a faster and lower cost basis to its customers. In addition, the company recently purchased and installed a suite of new research equipment that enables protein degradation studies which is a new and substantial line of business for the company. Our investment in new equipment, combined with our proprietary existing equipment, expands the company’s capabilities to include temperature-controlled humidity chamber analysis, temperature-controlled photo-stability analysis, differential scanning calorimetry, viscometry analysis, UV/Vis spectroscopy analysis, High Performance Liquid Chromatography (HPLC), a state-of-the-art automated dynamic laser light scattering system (DLS), free flow particle microscopic analysis, circular dichroism analysis, electron microscopy and high resolution mass spectrometry. Soluble Biotech is also planning to begin the development of an FDA-approved GMP facility to further support pharmaceutical needs. We have already secured a sizable contract and we are bidding on several more. I expect Soluble Biotech to be generating revenues by the end of the year.

As you can see, a lot is happening. Much is occurring under the radar. Much doesn’t make for a press release. However, don’t be discouraged by the lack of “blockbuster” announcements. We are moving forward rapidly and we expect the fourth quarter to be eventful. I will make myself available to shareholders who may wish to speak with me.

Sincerely,

Carl Schwartz CEO Predictive Oncology

[FROZENFLAME]

A new high on the way .

[Bona Vista]

I WONDER HOW MANAGEMENT CAN EXPLAIN WHY IF POAI AS A COMPANY IS DOING SO WONDERFUL, THEN WHY HAS ITS STOCK PRICE GONE FROM $2.00 DOWN TO $.81 QUICKLY.

LIKE I HAVE CONSISTENTLY POSTED TIME AND AGAIN, POAI IS NOTHING MORE THAN A SCAM COMPANY, MAKING MONEY FOR CEO AND HIS FAMILY WHILE TRYING TO CONVINCE PEOPLE OF A PRODUCT OR PRODUCTS IT DOESN'T HAVE.

DILUTION AND R/S IS THEIR PRODUCT OF VALUE, SEE YOU AT $.65 NEXT MONTH BEFORE R/S IN NOV-DEC 2020.

[Bona Vista]

IT'S TIME ALREADY FOR POAI TO CLOSE SHOP AND FILE FOR BANKRUPTCY, THIS COMPANY IS NOTHING BUT A SCAM WHOSE SHAREHOLDERS CONSIST OF MAYBE 50-65 INVESTORS.

POAI HAS NO REAL PRODUCT OF VALUE THAT ANY INSTITUTION WOULD BUY UNLESS THE COMPANY BRIBED THEM WITH FREE SHARES OF ITS STOCK, WHICH OF COURSE ARE WORTHLESS ON THE MARKET.

HOW MUCH LONGER CAN MANAGEMENT CONTINUE TO DILUTE THE COMPANY'S SHARE STRUCTURE AND KEEP USING R/S AS A MEANS TO REMAIN ON THE NASDAQ, ANYONE WHO CONSIDERS INVESTING IN THIS CRAP NEEDS TO GET THEIR HEAD EXAMINED AND THAT INCLUDES MYSELF.

[Bona Vista]

From the lack of Posters for POAI on this message board and other such venues, only reinforces what I have always believed about this company.

Firstly, POAI has absolutely NO following by anyone, especially the analysts and major investors.

Secondly, this company has absolutely NO product that is worth anything and is business only to line the CEO and his buddies pockets.

Thirdly, the only thing management does is dilute share price, offreing New and Lower option incentives inorder to keep its one or two fulltime employees, and of course last but Not least the continued R/S each and every year so that the company can remain above $1.00 for NASDAQ compliance regulations.

Management should be ashamed to continue having POAI listed and should just declare bankruptcy, unfortunately, they need money to live and therefore the SCAM remains.

[Bona Vista]

I WONDER IF POAI BREAKS BELOW $1.00 THIS WEEK, GOOD CHANCE IT CAN HAPPEN AS NOTHING SEEMS TO WORK FOR THIS COMPANY.

FUNNY HOW THE SHARE PRICE CONTINUES LOWER, WHILE POAI RELEASES NEWS AS TO HOW GREAT THINGS ARE GOING YEAR AFTER YEAR, AND QT AFTER QT.

WORST TRADING STOCK!!!

[Bona Vista]

I WONDER IF POAI BREAKS BELOW $1.00 THIS WEEK, GOOD CHANCE IT CAN HAPPEN AS NOTHING SEEMS TO WORK FOR THIS COMPANY.

FUNNY HOW THE SHARE PRICE CONTINUES LOWER, WHILE POAI RELEASES NEWS AS TO HOW GREAT THINGS ARE GOING YEAR AFTER YEAR, AND QT AFTER QT.

WORST TRADING STOCK!!!

[Bona Vista]

DOES POAI HAVE MORE THAN 50 STOCK INVESTORS, I BELIEVE A COMPANY NEEDS A CERTAIN NUMBER TO BE ELIGIBLE TO BE LISTED ON NASDAQ.

WON'T BE LONG BEFORE POAI IS BACK INTO THE PENNY'S, FOLLOWED BY THEIR USUAL REVERSE SPLIT.

[Bona Vista]

BY FAR POAI IS THE WORST COMPANY TRADING ON THE STOCK EXCHANGE, NO MATTER WHAT THE COMPANY RELEASES GOOD OR BAD RESULTS IN THE STOCK PRICE TO GO DOWN.

IT'S QUITE OBVIOUS THAT NO INVESTOR, ANALYST, OR EVEN TRADER WANTS TO TOUCH THIS PIECE OF C--P, FROM THE LOOKS OF IT I BELIVE POAI IS GETTING READY FOR THEIR ANNUAL R/S.

[Bona Vista]

When a company has to call you to make sure you vote in their next stockholders meeting I guess they have to be very desperate, they need every investor to vote to have the number that they need to still remain on the NASDAQ.

Desperate times for POAI, how much longer can this company stay in business there is just so much dilution and reverse splits that a company can do, next week as usual lower prices lower Low's and more selling, who in their right mind would be an investor and stockholder in this company.